gefitinib has been researched along with Diarrhea in 63 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 34 (53.97) | 29.6817 |
2010's | 27 (42.86) | 24.3611 |
2020's | 2 (3.17) | 2.80 |
Authors | Studies |
---|---|
Barlesi, F; Besse, B; Boselli, L; Cassard, L; Chaput, N; Dorta, M; Grivel, J; Lacroix, L; Mazieres, J; Mezquita, L; Naigeon, M; NgoCamus, M; Planchard, D; Riudavets, M; Texier, M; Varga, A | 1 |
Cai, L; Lei, X; Sun, K; Zhao, Q | 1 |
Camidge, DR; Chand, VK; Fan, J; Freiwald, M; Gettinger, S; Groen, HJM; Horn, L; Janjigian, YY; Miller, VA; Pao, W; Smit, EF; Wang, B | 1 |
Dietel, M; Eberhardt, WEE; Muehlenhoff, L; Schirmacher, P; Schuette, W; Thomas, M; Zirrgiebel, U | 1 |
Argiris, A; Burtness, B; Forastiere, AA; Ghebremichael, M; Gilbert, J; Kolesar, JM; Lee, JW; Sachidanandam, K | 1 |
Chen, L; Huang, Y; Liu, J; Ma, Y; Wu, H; Zhao, H; Zhou, N | 1 |
Ito, H; Kobayashi, H; Miura, H; Miura, M; Narita, C; Niioka, T; Sato, K | 1 |
Ikegami, Y; Inoue, Y; Ishikawa, T; Nakagawa, H; Nakamura, Y; Sano, K; Suzuki, T; Yoshida, H | 1 |
Abbas, H; Blazeby, JM; Chatterjee, A; Dahle-Smith, A; Davoudianfar, M; Dutton, SJ; Falk, S; Ferry, DR; Fyfe, DW; Gamble, T; Garcia-Alonso, A; Harrison, M; Hubner, RA; Jankowski, J; Julier, P; Kerr, R; Mansoor, W; Peachey, L; Pearson, SR; Petty, RD; Thompson, J | 1 |
de Marinis, F; Del Signore, E; Di Maio, M; Gori, B; Passaro, A | 1 |
Gao, Z; Gu, Y; Guo, L; Guo, W; Hong, S; Shen, Y; Sun, Y; Wu, X; Xu, Q | 1 |
Ando, T; Hirose, Y; Ishikawa, T; Kameyama, H; Kobayashi, T; Kosugi, S; Koyama, Y; Maruyama, T; Minagawa, M; Nagahashi, M; Ohtsubo, A; Okabe, Y; Sakata, J; Shimada, Y; Takizawa, K; Wakai, T; Watanabe, S | 1 |
Kempf, E; Lacroix, L; Soria, JC | 1 |
Bowen, JM; Gibson, RJ; Van Sebille, YZ; Wardill, HR | 1 |
Bray, V; Ding, PN; Gebski, V; Gralla, RJ; Lee, CK; Links, M; Lord, SJ; Yang, JC | 1 |
Feng, Q; Fu, X; Hackshaw, A; Mao, C; Tang, J; Yang, Z; Zhang, Y | 1 |
Dunsford, J | 1 |
Li, JR; Li, LY; Wang, MZ; Wang, SL; Zhang, L; Zhang, XT; Zhong, W | 1 |
Guan, ZZ; Huang, H; Wang, ZQ; Xu, F; Xu, GC; Zhang, L; Zhang, Y; Zhao, HY | 1 |
Ayabe, E; Endo, M; Igawa, S; Kaira, K; Kaira, R; Murakami, H; Naito, T; Nakamura, Y; Ono, A; Shimoyama, R; Shukuya, T; Takahashi, T; Tsuya, A; Yamamoto, N | 1 |
Murakami, H; Ohashi, Y; Sakurai, M; Shino, M; Suzuki, K; Takahashi, T; Yamamoto, N | 1 |
Abe, K; Akasaka, K; Imai, Y; Imura, J; Kaburagi, T; Nagao, K; Ohmori, K; Sagara, H; Ueda, Y; Yasuda, S | 1 |
Giaccone, G; Hoekman, K; Jürgensmeier, JM; Meijerink, MR; Puchalski, TA; Punt, CJ; Robertson, J; Saunders, O; van Cruijsen, H; van Herpen, CM; Voest, EE; Witteveen, PO | 1 |
Gao, ZQ; Gu, AQ; Han, BH; Shi, CL; Wang, HM; Xiong, LW | 1 |
Barchuk, AS; Ievleva, AG; Imianitov, EN; Ivantsov, AO; Levchenko, EV; Matsko, DE; Mitiushkina, NV; Moiseenko, FV; Moiseenko, VM; Protsenko, SA; Semenov, II; Togo, AV | 1 |
Ballman, KV; Behrens, RJ; Buckner, JC; Dakhill, SR; Flynn, PJ; Giannini, C; Jaeckle, KA; James, CD; Krauss, JC; Schaefer, PL; Scheithauer, BW; Uhm, JH; Wu, W | 1 |
Allen, JW; Daw, NC; Furman, WL; Geyer, JR; McGregor, LM; McKibbin, T; Stewart, CF; Tagen, M; Zhao, W | 1 |
Baba, J; Ichikawa, K; Kagamu, H; Kondo, R; Koshio, J; Miyabayashi, T; Narita, I; Ota, T; Tanaka, H; Tanaka, J; Watanabe, S; Yoshizawa, H | 1 |
Assaraf, YG; D'Incecco, A; Danesi, R; Falcone, A; Giaccone, G; Giovannetti, E; Guchelaar, HJ; Lemos, C; Peters, GJ; Santoro, A; Scheffer, GL; Tibaldi, C; van der Straaten, T; Zucali, PA | 1 |
Fujita, S; Fukuhara, A; Hatachi, Y; Kim, YH; Masago, K; Mio, T; Mishima, M; Nagai, H; Sakamori, Y; Togashi, Y | 1 |
Iwamoto, Y; Katakami, N; Kobayashi, M; Matsui, K; Moriyama, A; Nakagawa, K; Sueoka-Aragane, N; Takada, M; Takeda, K; Yoshioka, H | 1 |
Douillard, JY; Jiang, GL; Kim, ES; Li, LY; Liao, ML; Milenkova, T; Sun, Y; Wu, YL | 1 |
Gao, H; Guo, W; Li, J; Liu, X; Qin, H; Qu, L; Tang, C; Wang, H; Wang, W; Wei, X | 1 |
Albanell, J; Averbuch, SD; Baselga, J; Bjork, T; Calvert, H; Feyereislova, A; Gianni, L; Harris, A; Kaye, SB; Kieback, DG; Ranson, M; Raymond, E; Rischin, D; Rojo, F; Swaisland, H | 1 |
Bartolini, S; Calandri, C; Cappuzzo, F; Ceresoli, GL; Crinò, L; Gregorc, V; Lombardo, L; Spreafico, A; Tamberi, S; Toschi, L; Villa, E | 1 |
Bartolini, S; Cappuzzo, F; Ceresoli, GL; Crinò, L; Gregorc, V; Villa, E | 1 |
Li, LY; Mu, XL; Wang, MZ; Wang, SL; Zhang, XT | 2 |
Ben-Porat, L; Heelan, RT; Heinemann, MH; Kris, MG; Miller, VA; Pao, W; Pizzo, BM; Sachs, DL; Shah, NT; Tyson, LB | 1 |
Baetz, T; Berry, S; Brundage, M; Canil, CM; Chi, KN; Douglas, L; Ernst, DS; Fisher, B; McKenna, A; Moore, MJ; Pollak, M; Seymour, L; Winquist, E | 1 |
Chu, DT; Wang, B; Zhang, XR | 2 |
Berlin, J; Davis, L; Giantonio, B; Haller, DG; O'Dwyer, PJ; Shults, J; Sun, W; Veronese, ML | 1 |
Campagnoli, E; Cavina, R; De Vincenzo, F; Latteri, F; Santoro, A; Soto Parra, HJ; Zucali, PA | 1 |
Hirashima, T; Kawahara, K; Kawase, I; Kobayashi, M; Matsui, K; Nakamura, Y; Nitta, T; Sasada, S; Takimoto, T | 1 |
Aoe, M; Date, H; Fujiwara, Y; Hotta, K; Kiura, K; Matsuo, K; Tabata, M; Takigawa, N; Tanimoto, M; Tokumo, M; Toyooka, S | 1 |
Cersosimo, RJ | 1 |
Hashizume, T; Kobayashi, N; Kozawa, S; Miyazawa, N; Ogura, T; Tagawa, A; Takahashi, H; Watanuki, Y | 1 |
Sipples, R | 1 |
Asahina, H; Dosaka-Akita, H; Fujita, Y; Harada, M; Ishida, T; Isobe, H; Kinoshita, I; Kojima, T; Nishimura, M; Ogura, S; Okamoto, Y; Sukoh, N; Yamazaki, K; Yokouchi, H | 1 |
Yu, SY; Zhang, L | 1 |
Baker, SD; Cusatis, G; Gregorc, V; Hidalgo, M; Ingersoll, RG; Li, J; Ludovini, V; Sparreboom, A; Spreafico, A; Verweij, J; Villa, E | 1 |
Guan, ZZ; Pan, ZK; Wang, ZQ; Xu, F; Xu, GC; Zhang, L; Zhang, Y; Zhao, HY | 1 |
Asomaning, K; Christiani, DC; Gurubhagavatula, S; Heist, R; Liu, G; Lynch, TJ; Su, L; Wang, Z; Yeap, BY; Zhou, W | 1 |
Chen, XQ; Rong, TH; Wei, WD; Wen, ZS; Wu, HY | 1 |
Han, Y; Li, YM; Liu, XQ; Song, ST; Xu, JM; Yang, WW; Zhang, Y | 1 |
Boselli, S; de Braud, F; Lorizzo, K; Magni, E; Martignetti, A; Massacesi, C; Santoro, L; Zampino, MG; Zaniboni, A; Zorzino, L | 1 |
Barba, MC; Barbaro, B; Boz, G; De Paoli, A; Doglietto, GB; Frattegiani, A; Gambacorta, MA; Innocente, R; Lupattelli, M; Mantini, G; Ratto, C; Rossi, C; Valentini, V; Vecchio, FM | 1 |
Li, AW; Xu, JF; Zhou, CC | 1 |
Li, LY; Wang, HZ; Wang, MZ; Wang, SL; Wu, C; Zhang, L; Zhang, XT; Zhong, W | 1 |
Norman, P | 1 |
7 review(s) available for gefitinib and Diarrhea
Article | Year |
---|---|
A meta-analysis of the therapeutic effect of gefitinib combined with chemotherapy and chemotherapy alone in treating non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Progression-Free Survival; Thrombocytopenia; Treatment Outcome | 2020 |
Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Survival Rate | 2017 |
Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Gefitinib; Humans; Lung Neoplasms; Mutation; Outcome Assessment, Health Care; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2017 |
Nursing management of epidermal growth factor receptor inhibitor-induced toxicities.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Diarrhea; Drug Eruptions; Drug Monitoring; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Nursing Assessment; Oncology Nursing; Panitumumab; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; Severity of Illness Index | 2008 |
Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Quinazolines | 2010 |
Gefitinib: an adverse effects profile.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Dose-Response Relationship, Drug; Drug Interactions; ErbB Receptors; Exanthema; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2006 |
Common side effects of anti-EGFR therapy: acneform rash.
Topics: Acneiform Eruptions; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Diarrhea; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Nurse's Role; Oncology Nursing; Patient Education as Topic; Quinazolines; Severity of Illness Index | 2006 |
28 trial(s) available for gefitinib and Diarrhea
Article | Year |
---|---|
Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation | 2022 |
Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Cohort Studies; Diarrhea; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2017 |
Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Economics, Pharmaceutical; ErbB Receptors; Exanthema; Female; Gefitinib; Germany; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Outcome Assessment, Health Care; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2018 |
Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Diarrhea; Docetaxel; Drug Administration Schedule; ErbB Receptors; Fatigue; Female; Gefitinib; Genotype; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Taxoids; Treatment Outcome | 2013 |
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Deglutition Disorders; Diarrhea; Disease Progression; Disease-Free Survival; Double-Blind Method; Drug Eruptions; Eating; Esophageal Neoplasms; Fatigue; Female; Gefitinib; Humans; Male; Middle Aged; Pain; Proportional Hazards Models; Quality of Life; Quinazolines; Retreatment | 2014 |
[Efficacy and safety of gefitinib in maintenance therapy for patients with advanced non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Exanthema; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Quinazolines; Remission Induction; Smoking; Survival Rate | 2008 |
Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Therapy, Combination; ErbB Receptors; Fatigue; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasms; Netherlands; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome; Young Adult | 2010 |
[Clinical observation of gefitinib for the treatment of 125 cases with advanced non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diarrhea; Disease-Free Survival; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Survival Rate | 2010 |
[Effectiveness of gefitinib (Iressa) as first-line therapy for inoperable non-small-cell lung cancer with mutated EGFR gene (phase II study)].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Drug Eruptions; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2010 |
Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Dexamethasone; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Enzyme Activators; ErbB Receptors; Female; Gefitinib; Gene Amplification; Genes, erbB-1; Glioblastoma; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Quinazolines; Young Adult | 2011 |
Phase II study of gefitinib as a first-line therapy in elderly patients with pulmonary adenocarcinoma: West Japan Thoracic Oncology Group Study 0402.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Agents; Diarrhea; Disease-Free Survival; Drug Eruptions; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Smoking; Treatment Outcome | 2011 |
[Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Stomatitis; Treatment Outcome | 2012 |
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Prostatic Neoplasms; Quinazolines; Skin; Treatment Outcome | 2002 |
Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC).
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Skin Diseases | 2004 |
Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial.
Topics: Adult; Aged; Antineoplastic Agents; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Quinazolines; Radiography; Skin Diseases; Survival Analysis; Treatment Outcome | 2004 |
Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme.
Topics: Acne Vulgaris; Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diarrhea; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Quinazolines; Remission Induction; Stomatitis; Treatment Outcome | 2004 |
Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fatigue; Gefitinib; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines | 2005 |
A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dehydration; Diarrhea; Drug Interactions; Female; Fluorouracil; Gefitinib; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Quinazolines; Treatment Outcome | 2005 |
Non-small-cell lung cancer patients unsuitable for first-line chemotherapy: a new category of patients for clinical studies?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Patient Selection; Quinazolines; Survival Analysis; Treatment Outcome | 2005 |
A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Pruritus; Quinazolines; Treatment Outcome | 2006 |
[Gefitinib in the treatment of advanced non-small-cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quality of Life; Quinazolines; Remission Induction; Survival Analysis | 2006 |
Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Diarrhea; Disease-Free Survival; ErbB Receptors; Exanthema; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Homozygote; Humans; Introns; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Polymorphism, Genetic; Promoter Regions, Genetic; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Treatment Outcome | 2008 |
[Efficacy of gefitinib on advanced non-small cell lung cancer of bilateral diffuse or unilateral giant mass type].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diarrhea; Disease-Free Survival; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pruritus; Quality of Life; Quinazolines; Remission Induction | 2007 |
[Safety and efficacy of gefitinib for treatment of advanced non-small cell lung cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diarrhea; Disease Progression; Exanthema; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Remission Induction; Sex Factors; Treatment Outcome | 2007 |
First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Disease Progression; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Patient Dropouts; Quinazolines; Time Factors; Treatment Outcome | 2007 |
Infusional 5-fluorouracil and ZD1839 (Gefitinib-Iressa) in combination with preoperative radiotherapy in patients with locally advanced rectal cancer: a phase I and II Trial (1839IL/0092).
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Diarrhea; Drug Tolerance; Female; Fluorouracil; Gastrointestinal Diseases; Gefitinib; Humans; Infusions, Intravenous; Male; Neoplasm Staging; Quinazolines; Radiotherapy Dosage; Rectal Neoplasms; Safety | 2008 |
[Gefitinib in the treatment of refractory non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; ErbB Receptors; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Quality of Life; Quinazolines; Remission Induction; Survival Rate | 2007 |
[Gefitinib in the treatment of advanced non-small cell lung cancer with brain metastasis].
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; ErbB Receptors; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Quinazolines; Survival Rate | 2007 |
28 other study(ies) available for gefitinib and Diarrhea
Article | Year |
---|---|
[The cost-effectiveness analysis of gefitinib or erlotinib in the treatment of advanced EGFR mutant non-small cell lung cancer patients].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Cost-Benefit Analysis; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Insurance, Health; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Patient Outcome Assessment; Protein Kinase Inhibitors; Quinazolines | 2013 |
A limited sampling strategy for estimation of the area under the plasma concentration-time curve of gefitinib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Diarrhea; Drug Monitoring; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; ROC Curve; Sensitivity and Specificity; Specimen Handling; Time Factors | 2014 |
Gefitinib enhances the antitumor activity of CPT-11 in vitro and in vivo by inhibiting ABCG2 but not ABCB1: a new clue to circumvent gastrointestinal toxicity risk.
Topics: Administration, Oral; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Line, Tumor; Cell Survival; Diarrhea; Drug Synergism; Drug Therapy, Combination; Female; Gefitinib; HEK293 Cells; Humans; Irinotecan; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Quinazolines; RNA, Messenger; Transplantation, Heterologous | 2013 |
management of nonhematologic toxicities associated with different EGFR-TKIs in advanced NSCLC: a comparison analysis.
Topics: Afatinib; Anti-Bacterial Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Feeding Behavior; Gefitinib; Humans; Incidence; Lung Neoplasms; Mucositis; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Withholding Treatment | 2014 |
EGFR inhibitor-driven endoplasmic reticulum stress-mediated injury on intestinal epithelial cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line; Crown Ethers; Diarrhea; Endoplasmic Reticulum Stress; ErbB Receptors; Gefitinib; Intestinal Mucosa; Protein Kinase Inhibitors; Quinazolines; Rats | 2014 |
[A Case of Pneumatosis Cystoides Intestinalis Secondary to Gefitinib Therapy for Lung Adenocarcinoma].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Diarrhea; Gefitinib; Humans; Lung Neoplasms; Male; Pneumatosis Cystoides Intestinalis; Quinazolines; Tomography, X-Ray Computed; Vomiting | 2015 |
First Reported Case of Unexpected Response to an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the I744M Uncommon EGFR Mutation.
Topics: Aged; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Diarrhea; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Respiratory Sounds; Treatment Outcome | 2015 |
Gastrointestinal toxicities of first and second-generation small molecule human epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Quinazolinones | 2016 |
[Analysis of the efficacy and safety of gefitinib in the treatment of recurrent advanced non-small cell lung cancer in an expanded access program (EAP)].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Quinazolines; Remission Induction; Survival Rate; Young Adult | 2009 |
[Comparative evaluation of adverse reactions between gefitinib and erlotinib treatments in the same patients].
Topics: Aged; Anorexia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2009 |
Gefitinib: a second look. Non-small cell lung cancer: still very disappointing.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Diarrhea; Docetaxel; Drug Approval; ErbB Receptors; France; Gefitinib; Humans; Lung Diseases, Interstitial; Protein Kinase Inhibitors; Quinazolines; Skin Diseases; Taxoids | 2009 |
Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Diarrhea; DNA; Female; Gefitinib; Genotype; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Polymorphism, Genetic; Quinazolines | 2010 |
Epidermal growth factor receptor polymorphisms and risk for toxicity in paediatric patients treated with gefitinib.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Clinical Trials as Topic; Diarrhea; Drug Eruptions; ErbB Receptors; Exanthema; Gefitinib; Germ-Line Mutation; Humans; Infant; Neoplasms; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Young Adult | 2010 |
Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retreatment; Retrospective Studies; Treatment Outcome | 2011 |
Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Diarrhea; Female; Gefitinib; Genome-Wide Association Study; Genotype; Haplotypes; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Polymorphism, Genetic; Precision Medicine; Quinazolines; Treatment Outcome | 2011 |
Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Dosage Calculations; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Japan; Liver Function Tests; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Population Groups; Quinazolines; Retrospective Studies; Skin Diseases; Treatment Failure | 2011 |
[Efficacy and safety of gefitinib or docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who had failed previous platinum-based first-line chemotherapy].
Topics: Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Docetaxel; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Neutropenia; Platinum; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Survival Rate; Taxoids | 2011 |
Gefitinib (Iressa) for advanced non-small cell lung cancer.
Topics: Biological Availability; Carcinoma, Non-Small-Cell Lung; Controlled Clinical Trials as Topic; Diarrhea; Drug Interactions; ErbB Receptors; Gefitinib; Half-Life; Lung Neoplasms; Multicenter Studies as Topic; Quinazolines | 2002 |
Practical management of patients with non-small-cell lung cancer treated with gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Interactions; ErbB Receptors; Exanthema; Eye; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Patient Education as Topic; Quinazolines; Radiography | 2005 |
[IRESSA in the treatment of advanced non-small-cell lung cancer patients who failed to respond previous chemotherapy].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Remission Induction | 2004 |
[Treatment of non-small cell lung cancer with gefitinib].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Quinazolines; Treatment Outcome | 2005 |
Gefitinib for previously untreated patients with non-small cell lung cancer (NSCLC)--a retrospective study of 12 patients treated in one institution.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Diarrhea; Drug Eruptions; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Retrospective Studies | 2005 |
Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Diarrhea; ErbB Receptors; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Quinazolines; Retrospective Studies | 2006 |
[Gefitinib as a first-line therapy in patients with advanced non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Female; Gefitinib; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Quinazolines; Remission Induction; Retrospective Studies; Survival Rate | 2006 |
Pharmacogenetics of ABCG2 and adverse reactions to gefitinib.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Diarrhea; ErbB Receptors; Gefitinib; Genetic Variation; Humans; Neoplasm Proteins; Neoplasms; Polymorphism, Genetic; Quinazolines; Skin | 2006 |
[Efficacy of gefitinib on advanced non-small cell lung cancer in expanded access program (EAP)].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Survival Rate; Young Adult | 2006 |
[Gefitinib in the treatment of male patients with advanced non-small-cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; ErbB Receptors; Exanthema; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Remission Induction; Survival Rate | 2007 |
ZD-1839 (AstraZeneca).
Topics: Anemia; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Diarrhea; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Tolerance; Drugs, Investigational; Economics, Pharmaceutical; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Nausea; Pancreatic Neoplasms; Quinazolines; Tumor Cells, Cultured | 2001 |